Kodu・Aktsiate loetelu・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Suletud

SektorTervishoid

292.49 1.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

284.95

Max

292.43

Põhinäitajad
By Trading Economics
Sissetulek	62M 49M
Müük	12M 64M
P/E Sektori keskmine	30.235 57.002
Aktsiakasum	2.22
Kasumimarginaal	76.159
Töötajad	47
EBITDA	87M 72M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+21.48% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	42M 5.9B
Eelmine avamishind	290.69
Eelmine sulgemishind	292.49

Uudiste sentiment

By Acuity

21%

79%

52 / 340 Pingereas Healthcare

Ligand Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12. aug 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11. aug 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10. aug 2026, 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7. aug 2026, 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6. aug 2026, 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5. aug 2026, 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3. aug 2026, 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31. juuli 2026, 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30. juuli 2026, 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29. juuli 2026, 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28. juuli 2026, 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27. juuli 2026, 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24. juuli 2026, 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23. juuli 2026, 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21. juuli 2026, 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Võrdlus sarnastega

Hinnamuutus

Ligand Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

21.48% tõus

12 kuu keskmine prognoos

Keskmine 350.86 USD 21.48%

Kõrge 390 USD

Madal 326 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ligand Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ligand Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

52 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.